Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial (2019)
Attributed to:
Randomised trials in cardiovascular and metabolic disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.clinthera.2019.06.012
PubMed Identifier: 31447131
Publication URI: http://europepmc.org/abstract/MED/31447131
Type: Journal Article/Review
Parent Publication: Clinical Therapeutics
Issue: 9
ISSN: 0149-2918